BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Citrome L. Vortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract. 2014;68:60-82. [PMID: 24165478 DOI: 10.1111/ijcp.12350] [Cited by in Crossref: 45] [Cited by in F6Publishing: 24] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Ciranna L, Catania MV. 5-HT7 receptors as modulators of neuronal excitability, synaptic transmission and plasticity: physiological role and possible implications in autism spectrum disorders. Front Cell Neurosci 2014;8:250. [PMID: 25221471 DOI: 10.3389/fncel.2014.00250] [Cited by in Crossref: 57] [Cited by in F6Publishing: 46] [Article Influence: 8.1] [Reference Citation Analysis]
2 Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Saf 2015;14:1291-304. [PMID: 26022537 DOI: 10.1517/14740338.2015.1046836] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
3 Pearce EF, Murphy JA. Vortioxetine for the treatment of depression. Ann Pharmacother 2014;48:758-65. [PMID: 24676550 DOI: 10.1177/1060028014528305] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
4 Berhan A, Barker A. Vortioxetine in the treatment of adult patients with major depressive disorder: a meta-analysis of randomized double-blind controlled trials. BMC Psychiatry 2014;14:276. [PMID: 25260373 DOI: 10.1186/s12888-014-0276-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
5 Khoo SY, Brown RM. Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA? CNS Drugs 2014;28:713-30. [PMID: 24942635 DOI: 10.1007/s40263-014-0179-x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 32] [Article Influence: 7.0] [Reference Citation Analysis]
6 Koesters M, Ostuzzi G, Guaiana G, Breilmann J, Barbui C. Vortioxetine for depression in adults. Cochrane Database Syst Rev 2017;7:CD011520. [PMID: 28677828 DOI: 10.1002/14651858.CD011520.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
7 Villas Boas GR, Boerngen de Lacerda R, Paes MM, Gubert P, Almeida WLDC, Rescia VC, de Carvalho PMG, de Carvalho AAV, Oesterreich SA. Molecular aspects of depression: A review from neurobiology to treatment. Eur J Pharmacol 2019;851:99-121. [PMID: 30776369 DOI: 10.1016/j.ejphar.2019.02.024] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 13.5] [Reference Citation Analysis]
8 Sowa-kućma M, Pańczyszyn-trzewik P, Misztak P, Jaeschke RR, Sendek K, Styczeń K, Datka W, Koperny M. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant. Pharmacological Reports 2017;69:595-601. [DOI: 10.1016/j.pharep.2017.01.030] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
9 El Mansari M, Lecours M, Blier P. Effects of acute and sustained administration of vortioxetine on the serotonin system in the hippocampus: electrophysiological studies in the rat brain. Psychopharmacology (Berl) 2015;232:2343-52. [PMID: 25665528 DOI: 10.1007/s00213-015-3870-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
10 Castle D, Bosanac P, Rossell S. Treating OCD: what to do when first-line therapies fail. Australas Psychiatry 2015;23:350-3. [PMID: 26104775 DOI: 10.1177/1039856215590027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
11 Saltiel PF, Silvershein DI. Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatr Dis Treat 2015;11:875-88. [PMID: 25848287 DOI: 10.2147/NDT.S73261] [Cited by in Crossref: 11] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
12 Garnock-Jones KP. Vortioxetine: a review of its use in major depressive disorder. CNS Drugs 2014;28:855-74. [PMID: 25145538 DOI: 10.1007/s40263-014-0195-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
13 Bobo W, Kelliny M, Croarkin P, Moore K. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. TCRM. [DOI: 10.2147/tcrm.s55313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
14 Frampton JE. Vortioxetine: A Review in Cognitive Dysfunction in Depression. Drugs 2016;76:1675-82. [DOI: 10.1007/s40265-016-0655-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 6.8] [Reference Citation Analysis]
15 Deardorff WJ, Grossberg GT. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opin Pharmacother 2014;15:2525-42. [PMID: 25224953 DOI: 10.1517/14656566.2014.960842] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 3.9] [Reference Citation Analysis]
16 Sharma H, Santra S, Dutta A. Triple reuptake inhibitors as potential next-generation antidepressants: a new hope? Future Med Chem 2015;7:2385-406. [PMID: 26619226 DOI: 10.4155/fmc.15.134] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
17 Alvarez E, Perez V, Artigas F. Pharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder. Neuropsychiatr Dis Treat 2014;10:1297-307. [PMID: 25075188 DOI: 10.2147/NDT.S41387] [Cited by in Crossref: 38] [Cited by in F6Publishing: 12] [Article Influence: 5.4] [Reference Citation Analysis]
18 Citrome L. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders 2016;196:225-33. [DOI: 10.1016/j.jad.2016.02.042] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 6.2] [Reference Citation Analysis]
19 Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, Reines E. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol 2016;30:242-52. [PMID: 26864543 DOI: 10.1177/0269881116628440] [Cited by in Crossref: 63] [Cited by in F6Publishing: 42] [Article Influence: 12.6] [Reference Citation Analysis]
20 Citrome L. Vilazodone, levomilnacipran and vortioxetine for major depressive disorder: the 15-min challenge to sort these agents out. Int J Clin Pract 2015;69:151-5. [DOI: 10.1111/ijcp.12620] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
21 Wang S, Han C, Pae C. Criticisms of drugs in early development for the treatment of depression: what can be improved? Expert Opinion on Investigational Drugs 2015;24:445-53. [DOI: 10.1517/13543784.2014.985784] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
22 Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors). CNS Spectr 2015;20:93-7. [PMID: 25831967 DOI: 10.1017/S1092852915000139] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
23 Tritschler L, Felice D, Colle R, Guilloux J, Corruble E, Gardier AM, David DJ. Vortioxetine for the treatment of major depressive disorder. Expert Review of Clinical Pharmacology 2014;7:731-45. [DOI: 10.1586/17512433.2014.950655] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
24 Mago R, Tripathi N, Andrade C. Cardiovascular adverse effects of newer antidepressants. Expert Review of Neurotherapeutics 2014;14:539-51. [DOI: 10.1586/14737175.2014.908709] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.1] [Reference Citation Analysis]